Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Published:2013-08-13 Issue:10 Volume:8 Page:2145-2150
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Kim Hyung-Gu¹,Tan Li,Weisberg Ellen L.,Liu Feiyang²,Canning Peter³,Choi Hwan Geun,Ezell Scott A.¹,Wu Hong²,Zhao Zheng²,Wang Jinhua,Mandinova Anna¹,Griffin James D.,Bullock Alex N.³,Liu Qingsong²,Lee Sam W.¹,Gray Nathanael S.

Affiliation:

1. Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, United States

2. High Magnetic Field laboratory, Chinese Academy of Sciences, P.O. Box 1110, Hefei, Anhui, 230031, P. R. China

3. Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, U.K.

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/cb400430t

Reference21 articles.

1. Discoidin domain receptor tyrosine kinases: new players in cancer progression

2. Discoidin domain receptor 1 (DDR1) signaling in PC12 cells: activation of juxtamembrane domains in PDGFR/DDR/TrkA chimeric receptors

3. Identification of expressed genes characterizing long-term survival in malignant glioma patients

4. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice

5. Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure‐Activity Relationship (SAR);ChemistrySelect;2024-08-06

2. Discovery of LLC355 as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1;Journal of Medicinal Chemistry;2024-05-10

3. DDR1-targeted therapies: current limitations and future potential;Drug Discovery Today;2024-05

4. Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1;Oncogene;2024-04-03

5. Identification of Ureidocoumarin-Based Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors via Drug Repurposing Approach, Biological Evaluation, and In Silico Studies;Pharmaceuticals;2024-03-27